Colin D. Weekes

15.6k citations

144 papers · 3.5k indexed · 3 hit papers · h-index 28

Oncology top 1%
- Pancreatic and Hepatic Oncology Research 67
- Colorectal Cancer Treatments and Studies 18
- Cancer Treatment and Pharmacology 14
- Cancer Immunotherapy and Biomarkers 13
Cancer Research top 2%
- Cancer Genomics and Diagnostics 35
Biotechnology top 2%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 15
- Renal cell carcinoma treatment 11
Epidemiology
- Neuroendocrine Tumor Research Advances 13

Co-authors: Wells A. Messersmith Sabine Eckhardt Stephen Leong John J. Arcaroli Todd M. Pitts Antonio Jimeno Aik Choon Tan John J. Tentler
Cited by: Oncology Cancer Research Biotechnology
Journals: Journal of Clinical Oncology (57 papers)Annals of Oncology (11 papers)Clinical Cancer Research (8 papers)
Partner nations: United States Germany Spain

In The Last Decade

Colin D. Weekes

137 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Medicine
2020 CA A Cancer Journal for Clinicians
2012 Nature Reviews Clinical Oncology

Peers

Countries citing papers authored by Colin D. Weekes

Since Specialization

Citations

This map shows the geographic impact of Colin D. Weekes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin D. Weekes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin D. Weekes more than expected).

Fields of papers citing papers by Colin D. Weekes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin D. Weekes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin D. Weekes. The network helps show where Colin D. Weekes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Colin D. Weekes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Colin D. Weekes Line = papers co-authored together Colin D. Weekes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results Nature Medicine ·Zev A. Wainberg,Colin D. Weekes,Muhammad Furqan,Pashtoon Murtaza Kasi,Craig Devoe,Alexis D. Leal,Vincent Chung,James Perry,Thian Kheoh,Lisa K. McNeil,A. I. Kokshaisky,Peter C. DeMuth,C. Haqq,Shubham Pant,Eileen M. O’Reilly	2025	7
2	Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal of Clinical Oncology ·Deirdre Jill Cohen,Judith D. Goldberg,Lawrence P. Leichman,Tsivia Hochman,Elliot Newman,Kevin Du,Alec J. Megibow,Paul E. Oberstein,Raed Moh’d Taiseer Al-Rajabi,Aaron J. Scott,Tanios Bekaii‐Saab,Wells A. Messersmith,Colin D. Weekes	2024	1
3	Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialbreakdown → Nature Medicine ·Shubham Pant,Zev A. Wainberg,Colin D. Weekes,Muhammad Furqan,Pashtoon Murtaza Kasi,Craig Devoe,Alexis D. Leal,Vincent Chung,Olca Baştürk,Simachew Amogne Debas,Tommi Haryadi Mukhidin,Citra Kusumadewi,James Perry,Thian Kheoh,Lisa K. McNeil,A. I. Kokshaisky,Peter C. DeMuth,Christopher M. Haqq,Eileen M. O’Reilly	2024	124
4	A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors Clinical Cancer Research ·Gregory M. Coté,Bose Kochupurakkal,T. Khanh,Andrea J. Bullock,Michael L. Cheng,Alona Muzikansky,Daniel E. McLoughlin,James M. Cleary,Tamara Hubetska,Aparna R. Parikh,Jong Chul Park,Colin D. Weekes,Oladapo Yeku,Lee Zou,Geoffrey I. Shapiro	2024	4
5	Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer The Lancet Oncology ·Priyadarshini Pathak,Colin D. Weekes,Jennifer Y. Wo	2024	2
6	SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials. Journal of Clinical Oncology ·Hannah Roberts,Hamed Baradaran,Beow Y. Yeap,Julie L. Koenig,Aparna R. Parikh,Jeffrey W. Clark,David P. Ryan,Jill N. Allen,Colin D. Weekes,Lawrence S. Blaszkowsky,Priyadarshini Pathak,Lorraine C. Drapek,Leilana Ly,Theodore S. Hong,Jennifer Y. Wo	2024	0
7	664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors Annals of Oncology ·Ryan B. Corcoran,T. Khanh,James M. Cleary,Aparna R. Parikh,Oladapo Yeku,Colin D. Weekes,Leanne G. Ahronian,Gianluca Mauri,Ju Tian,Joan S. Brugge,Dejan Juric,K. T. Flaherty,Ryan J. Sullivan,Jeffrey W. Clark,Rebecca S. Heist,U. Matulonis,J.F. Liu,Geoffrey I. Shapiro	2023	1
8	The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation. Journal of Clinical Oncology ·Kenneth H. Yu,Colin D. Weekes,Демьяненко Светлана Геннадьевна,Merete Mauland,Alaruru O. Adeyanju,Parastoo B. Dahi,Sergio Giralt,Eileen M. O’Reilly	2023	0
9	Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology ·Colin D. Weekes,David T. Ting,Aparna R. Parikh,Josef Reislhuber,Claire Fabre,Viviana Cremasco,David A. Ruddy,Andrew S. Liss,Aileen O’Shea,Mukesh G. Harisinghani,Limin Wang,Jonathan Chang,Eunice L. Kwak,David P. Ryan	2023	1
10	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors Clinical Cancer Research ·Sara M. Tolaney,T. Khanh,Joseph P. Eder,Patricia LoRusso,Colin D. Weekes,Sarat Chandarlapaty,Ching‐Wei Chang,S. S. Bkhattacharya,達也辻井,Eduardo Augusto Costa,Flávia Brunstein,Montserrat Carrasco‐Triguero,Walter C. Darbonne,Jennifer M. Giltnane,W. Michael Flanagan,S. Renee Commerford,Alexander Ungewickell,Geoffrey I. Shapiro,Shanu Modi	2020	15
11	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·John H. Strickler,Colin D. Weekes,John Nemunaitis,Ramesh K. Ramanathan,Rebecca S. Heist,Daniel Morgensztern,Eric Angevin,Todd M. Bauer,Huibin Yue,Monica Motwani,Apurvasena Parikh,Edward B. Reilly,Daniel Afar,Louie Naumovski,Karen Kelly	2018	104
12	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology ·Dung T. Le,Andrew H. Ko,Zev A. Wainberg,Vincent J. Picozzi,Hedy L. Kindler,Andrea Wang‐Gillam,Paul E. Oberstein,Michael A. Morse,Herbert J. Zeh,Colin D. Weekes,Tony R. Reid,Aimee Murphy,Huang Shun-hong,Chan C. Whiting,Nitya Nair,Amanda Enstrom,Sandy Ferber,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee	2017	39
13	A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors Annals of Oncology ·Shanu Modi,Joseph P. Eder,Patricia LoRusso,Colin D. Weekes,Sarat Chandarlapaty,Sara M. Tolaney,Percy G. Jackson,D. Ross Camidge,Raja Abbas Ahmed Khan,達也辻井,谷口隆幸,Eduardo Augusto Costa,Flávia Brunstein,Walter C. Darbonne,W. Michael Flanagan,Alexander Ungewickell,Geoffrey I. Shapiro	2016	0
14	Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Annals of Oncology ·Colin D. Weekes,Suleiman Said Buba,Heinz‐Josef Lenz,Bert H. O’Neil,Wells A. Messersmith,S. Cohen,G. A. Akin,Safi Shahda,Ann M. Kapoun,M. Yoshida,Yu-Ting Hung,Fiore Cattaruzza,Lu Xu,Jakob Dupont,R. Brachmann,Shailaja Uttamsingh,Azeez Farooki,Efrat Dotan	2016	12
15	152O A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours Annals of Oncology ·Vincenzo Teneggi,Matthew Ng,David S.P. Tan,Vivek Subbiah,Colin D. Weekes,Malin Persson,Kantharaj Ethirajulu,Pauline Yeo,In-Chang Song,Geoffrey Dubois,Stéphanie Blanchard,Ranjani Nellore,Batya Brutin 'arbeit,Jeffrey Hill,David M. Virshup,Babita Madan,A. Matter	2016	10
16	Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies Clinical Cancer Research ·Daniel W. Bowles,Jennifer R. Diamond,Elaine T. Lam,Colin D. Weekes,David P. Astling,Ryan T. Anderson,Stephen Leong,Lia Gore,Marileila Varella‐Garcia,Brian W. Vogler,Stephen B. Keysar,中川洋,Dara L. Aisner,Chen Ren,Aik Choon Tan,François Wilhelm,Manoj Maniar,Sabine Eckhardt,Wells A. Messersmith,Antonio Jimeno	2014	54
17	Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer Clinical Cancer Research ·Colin D. Weekes,Daniel D. Von Hoff,Alex A. Adjei,刘曦子,Sabine Eckhardt,Lia Gore,Karl D. Lewis,Glen J. Weiss,Ramesh K. Ramanathan,Grace K. Dy,Wen Wang,Gianluca Fiorito,Cory Iverson,Jeffrey N. Miner,Zancong Shen,Li‐Tain Yeh,Ronald L. Dubowy,Michael Jeffers,Prabhu Rajagopalan,Neil J. Clendeninn	2013	46
18	Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer Clinical Cancer Research ·Wen Wee,Wells A. Messersmith,Grace K. Dy,Colin D. Weekes,J PEETERS,Chen Ren,Manoj Maniar,François Wilhelm,Sabine Eckhardt,Alex A. Adjei,Antonio Jimeno	2012	42
19	Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors Clinical Cancer Research ·Xin Yan,Jessica Li,Jenny Wu,G.A. Sedee,Colin D. Weekes,Amita Patnaik,Patricia LoRusso,Rainer K. Brachmann,Raymond K. Tong,Yibing Yan,Ryan J. Watts,Shuang Bai,Priti S. Hegde	2012	33
20	Culture Methods for the Detection of Minimal Tumor Contamination of Hematopoietic Harvests: A Review Journal of Hematotherapy ·John Sharp,Schnabel,Barbara Murphy,Colin D. Weekes	1995	22

About Colin D. Weekes

Colin D. Weekes is a scholar working on Oncology, Cancer Research and Biotechnology, having authored 144 papers that have together received 3.5k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (67 papers), Cancer Genomics and Diagnostics (35 papers), Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (14 papers), Neuroendocrine Tumor Research Advances (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Renal cell carcinoma treatment (11 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (758 citations) and Biotechnology (259 citations). Colin D. Weekes has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Wells A. Messersmith, Sabine Eckhardt, Stephen Leong, John J. Arcaroli, Todd M. Pitts, Antonio Jimeno, Aik Choon Tan, John J. Tentler, Anirban Maitra and William L. Hwang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact